Search
lenvatinib (Lenvima)
Indications:
- treatment of differentiated thyroid cancer that has progressed despite radioactive iodine therapy
Contraindications:
Caution
- control blood pressure prior to administration of lenvatinib
- withhold lenvatinib for hypertension stage 3 or stage 4 (BP > 180/110 mm Hg)
Dosage:
- 24 mg PO QD
Capsules: 10 mg, 4 mg
Dosage adjustment in renal failure:
- 14 mg PO QD for patients with severe renal failure
- 14 mg PO QD for patients with severe liver failure
Clinical significance:
- median progression-free survival: 18 months vs 4 months for placebo
- reduction in tumor size: 65% vs 2% for placebo
Adverse effects:
- most common
- hypertension
- fatigue
- diarrhea
- arthralgia, myalgia
- serious
- heart failure
- arterial thromboembolism & embolic stroke
- hepatotoxicity
General
small inhibitory antineoplastic agent (ib drug)
References
- FDA News Release. February 13, 2015.
FDA approves Lenvima for a type of thyroid cancer.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434288.htm
- Lenvatinib prescribing information
http://www.lenvima.com/pdfs/prescribing-information.pdf